Neurotrophic factors for the treatment of Parkinson's disease
- PMID: 21689963
- DOI: 10.1016/j.cytogfr.2011.05.001
Neurotrophic factors for the treatment of Parkinson's disease
Abstract
Parkinson's disease (PD) is a common neurodegenerative disorder caused by the progressive degeneration of the nigrostriatal dopaminergic pathway. The resulting loss of dopamine neurotransmission is responsible for the symptoms of the disease. Available treatments are initially successful in treating PD symptoms; however, their long-term use is associated with complications and they cannot stop the neurodegeneration. Current research aims at developing new therapies to halt/reverse the neurodegenerative process, rather than treating symptoms. Neurotrophic factors are proteins critical for maintenance and protection of neurones in the developing and adult brain. Several neurotrophic factors have been investigated for their protective effects on dopaminergic neurones. Here we review some of the most promising factors and provide an update on their status in clinical trials.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.Exp Neurol. 1993 Nov;124(1):103-18. doi: 10.1006/exnr.1993.1181. Exp Neurol. 1993. PMID: 8282068 Review.
-
Neurotrophic factors for the treatment of Parkinson's disease.Parkinsonism Relat Disord. 2007;13 Suppl 3:S321-8. doi: 10.1016/S1353-8020(08)70024-5. Parkinsonism Relat Disord. 2007. PMID: 18267258 Review.
-
Neurotrophic factors and Parkinson's disease: the emergence of a new player?Sci STKE. 2007 Nov 6;2007(411):pe60. doi: 10.1126/stke.4112007pe60. Sci STKE. 2007. PMID: 17986711
-
Sir-2.1 modulates 'calorie-restriction-mediated' prevention of neurodegeneration in Caenorhabditis elegans: implications for Parkinson's disease.Biochem Biophys Res Commun. 2011 Sep 23;413(2):306-10. doi: 10.1016/j.bbrc.2011.08.092. Epub 2011 Aug 26. Biochem Biophys Res Commun. 2011. PMID: 21889494
-
Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects.Med Hypotheses. 2007;69(6):1219-21. doi: 10.1016/j.mehy.2007.04.014. Epub 2007 Jun 4. Med Hypotheses. 2007. PMID: 17548170
Cited by
-
Transplantation of novel human GDF5-expressing CHO cells is neuroprotective in models of Parkinson's disease.J Cell Mol Med. 2012 Oct;16(10):2451-60. doi: 10.1111/j.1582-4934.2012.01562.x. J Cell Mol Med. 2012. PMID: 22436046 Free PMC article.
-
Dual modulation on glial cells by tetrahydroxystilbene glucoside protects against dopamine neuronal loss.J Neuroinflammation. 2018 May 25;15(1):161. doi: 10.1186/s12974-018-1194-5. J Neuroinflammation. 2018. PMID: 29801454 Free PMC article.
-
Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease.Int J Nanomedicine. 2014 May 27;9:2677-87. doi: 10.2147/IJN.S61940. eCollection 2014. Int J Nanomedicine. 2014. PMID: 24920904 Free PMC article.
-
Hypoxia inducible factor-1 as a target for neurodegenerative diseases.Curr Med Chem. 2011;18(28):4335-43. doi: 10.2174/092986711797200426. Curr Med Chem. 2011. PMID: 21861815 Free PMC article. Review.
-
A fibrin matrix promotes the differentiation of EMSCs isolated from nasal respiratory mucosa to myelinating phenotypical Schwann-like cells.Mol Cells. 2015 Mar;38(3):221-8. doi: 10.14348/molcells.2015.2170. Epub 2015 Feb 4. Mol Cells. 2015. PMID: 25666351 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical